The Mirels’ score is a widely utilized tool for assessing the risk of pathological fractures in patients with metastatic bone disease. This scoring system assists clinicians in estimating fracture likelihood based on clinical, radiological, and anatomical parameters, thereby guiding treatment decisions and management strategies. This review provides a comprehensive analysis of the Mirels’ score, detailing its development, clinical applications, and its role in predicting fractures across various metastatic cancers. Additionally, it discusses the score’s limitations, including its potential to over- or underestimate fracture risk, and explores recent advancements in imaging and biomarker technologies that may enhance or complement its predictive accuracy. By critically examining the existing literature, this review aims to offer a thorough understanding of the Mirels’ score’s strengths and weaknesses, while considering its future role in personalized cancer care.
Mirels评分是评估转移性骨病患者病理性骨折风险的常用工具。该评分系统通过临床、影像学和解剖学参数帮助临床医生评估骨折可能性，从而指导治疗决策和管理策略。本文综述对Mirels评分进行了全面分析，详细阐述其发展历程、临床应用及其在不同转移性癌症骨折预测中的作用。同时探讨了该评分的局限性，包括可能高估或低估骨折风险的问题，并研究了影像学和生物标志物技术的最新进展如何提升或补充其预测准确性。通过对现有文献的批判性分析，本综述旨在深入理解Mirels评分的优势与不足，并探讨其在个体化癌症治疗中的未来应用前景。
Advancements in Assessing Pathological Fracture Risk: News on Mirels’ Score
肿瘤(癌症)患者之家